Shalini Sharp - 14 Oct 2026 Form 4 Insider Report for Iambic Therapeutics, Inc. (IAM)

Reporting relationship
Director
Issuer ticker
IAM
Reported as of
14 Oct 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
16 Oct 2026, 16:22:59 UTC
Prior SEC filing
30 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Sunny Chang, by power of attorney
Filing notes and source

Key filing fact

Shalini Sharp filed Form 4 for Iambic Therapeutics, Inc. (IAM) on 16 Oct 2026.

Key facts

  • This page summarizes Shalini Sharp's Form 4 filing for Iambic Therapeutics, Inc. (IAM).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 16 Oct 2026, 16:22.

Change

  • Previous filing in this sequence was filed on 30 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001377202 Primary reporting owner

Sharp Shalini

Relationship
Director
Address
C/O IAMBIC THERAPEUTICS, INC., 5627 OBERLIN DRIVE, SUITE 120, SAN DIEGO
Signature
/s/ Sunny Chang, by power of attorney
Signature date
16 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IAM transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+20,300
Change %
Price
$0.000000*
Shares after
20,300
Date
14 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
20,300
Exercise price
$16.00
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

All of the shares subject to the option vest on October 14, 2027.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .